Avion Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Avion Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-84	Closed	–	–	1551
2025 Q1	$0	Buy	+84	New	+$612	﹤0.01%	1320

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Avion Wealth's RXRX Position: Q2 2025 in Review

Avion Wealth sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 84 shares.

Avion Wealth first reported a position in RXRX in Q1 2025 and held it in 1 quarter. The position peaked at $0 in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

Avion Wealth reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Avion Wealth sold 84 Recursion Pharmaceuticals shares in Q2 2025.
Avion Wealth first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Avion Wealth's Recursion Pharmaceuticals position peaked at $0 in Q1 2025.
332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.